Search

News Inclisiran −⁠ a new addition to the arsenal of dyslipidemia treatment

At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule −⁠ inclisiran were presented at the Novartis company symposium.

Source: Chronic Heart Failure and Lipidology 23. 12. 2022

News Expression of PD-L1 in Patients with Advanced Non-Small Cell Lung Cancer

An international team of authors published a systematic review addressing the relationship between the programmed cell death receptor ligand (PD-L1) and important clinical characteristics of patients with non-small cell lung cancer (NSCLC), the significance of PD-L1 expression for NSCLC prognosis, and the potential use of this biomarker to predict the response of patients with advanced/metastatic NSCLC to therapies targeting the PD-1/PD-L1 pathway.

Source: Immunotherapy in Oncology 14. 11. 2020

News Incidence of Osteoporosis in Patients with Atrial Fibrillation Treated with Different Oral Anticoagulants

Previous research has suggested an increased risk of osteoporosis and osteoporotic fractures in patients with atrial fibrillation treated with warfarin. A recent analysis also identified a higher incidence of osteoporosis in patients treated with warfarin or direct oral anticoagulants (DOACs). However, less is known about the risk of this disease when using DOACs compared to warfarin. Therefore, Australian doctors compared its incidence in patients treated with different oral anticoagulants for atrial fibrillation (AF) in a population cohort study using data from a nationwide primary care database.

Source: Anticoagulant Treatment 16. 10. 2023

News Meta-analysis of Efficacy and Safety of Antidiabetics in Treating Gestational DM

What efficacy and safety do insulin, metformin, or the sulfonylurea derivative glibenclamide (glyburide) offer in lowering glucose levels in women with gestational diabetes? The authors of a meta-analysis of randomized controlled trials used a probabilistic model –⁠ a Bayesian network –⁠ to answer this question.

Source: Modern Treatment of Diabetes 13. 9. 2023

News Current and Future Possibilities for Influencing Immune Thrombocytopenia

The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some patients, optimal treatment is still not available, and their hope lies in further research.

Source: Immune Thrombocytopenia 16. 5. 2022

Články časopisu Current treatment options for hepatocellular carcinoma

Author of the article: MUDr. Kubala Eugen Source: Klinická onkologie | Supplementum 3/2020 31. 10. 2020

Články časopisu Efficiency of Robot-assisted Therapy through the Device Armeo Spring in Patients after Stroke in Acute Phase of Early Rehabilitation

Author of the article: R. Bocanová, T. Gueye, O. Švestková, A. Oktábcová Source: Rehabilitation & Physical Medicine | 3/2018 23. 8. 2018

News Comparison of Enoxaparin and Unfractionated Heparin in Hospitalized Patients in Terms of Clinical and Cost Effectiveness

Thromboembolic disease represents one of the severe complications in hospitalized patients. Low molecular weight and unfractionated heparin are most commonly used during hospitalization as part of pharmacological thromboprophylaxis. An extensive study conducted in the United States evaluated the clinical and cost-effectiveness and safety of both therapy modalities in hospitalized patients at risk of thromboembolic disease.

Source: Thromboprophylaxis 31. 3. 2022

News Metamizole in Pain Management for Patients with Subarachnoid Hemorrhage

A study by Czech authors from the University Hospital St. Anna in Brno, recently published in the British Journal of Neurosurgery, evaluated analgesic treatment in patients with subarachnoid hemorrhage. The use of metamizole as the primary analgesic was associated with a significantly lower risk of adverse clinical outcomes at 2 weeks and 6 months compared to other non-opioid and opioid analgesics.

Source: Analgesia 10. 5. 2023

News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer

The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.

Source: Breast Carcinoma 28. 5. 2020

Články časopisu Advances in the therapy of small cell lung cancer

Author of the article: D. Vrána Source: Klinická onkologie | Supplementum 1/2021 27. 5. 2021

News Overlap of SGLT2 Inhibitors from Diabetology to Cardiology

As recent research shows, one of the modern groups of antidiabetic drugs -⁠ SGLT2 inhibitors, also known as gliflozins -⁠ brings benefits not only in diabetology but also in cardiology and nephrology. It has been confirmed that representatives of this class of drugs prolong patients' lives, reduce the incidence of major cardiovascular (CV) events and the risk of heart failure (HF), and improve renal function. A recently published study additionally indicates that the CV benefit of empagliflozin is independent of the number of compensated CV risk factors and manifests within the first 3 months of treatment.

Source: Diabetes 29. 10. 2021

News Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism

Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75 µg), creating obstacles for some patients to achieve an optimal maintenance dose. The availability of tablets that allow for dosing in between these values facilitates precise and effective titration of levothyroxine doses, especially at the lower end of the spectrum.

Source: Thyroid Disorders 23. 2. 2024

News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?

In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature –⁠ this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.

Source: Cardiovascular Continuum 25. 10. 2023

News Progress on Lorlatinib –⁠ What's Next?

Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing –⁠ to continue with lorlatinib.

Source: Genetic Profile and Treatment of NSCLC 17. 5. 2022